Scarica l'app Stockscreener
3.25
3.56%
-0.12
Macrogenics Inc Borsa (MGNX) Ultime notizie
MacroGenics stock has October 23 data ahead in 2026 - ad-hoc-news.de
MacroGenics doses first patient in MGC030 cancer trial By Investing.com - Investing.com India
A patient has received the first dose of a new cancer treatment. - Stock Titan
Form 4 MacroGenics Inc For: 10 October By Investing.com - Investing.com Nigeria
Form 4 MacroGenics Inc For: 10 October By Investing.com - Investing.com UK
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
MacroGenics insider exercises 8,000 options for MacroGenics stock - AD HOC NEWS
MacroGenics stock fell 2.47 percent on October 7 with pipeline data ahead - AD HOC NEWS
Ezio Bonvini Executes 8,000 MacroGenics Stock Options at $2.60 Each - Kalkine Media
At $2.60 a share, MacroGenics (MGNX) research chief exercises options for 8,000 shares. - Stock Titan
MacroGenics stock faces October data after a Q2 revenue miss - AD HOC NEWS
MacroGenics reports revenue miss and gets USD 6.33 target for MacroGenics stock - AD HOC NEWS
MacroGenics reports revenue miss and gets USD 6.33 target for MacroGenics stock - AD HOC NEWS
Current ratio of MacroGenics, Inc. – HAN:M55 - tradingview.com
MacroGenics, Inc. Revenue Breakdown – HAN:M55 - tradingview.com
Form 144 MACROGENICS INC. For: 27 September By Investing.com - Investing.com Australia
Form 144 MACROGENICS INC. For: 27 September By Investing.com - Investing.com Nigeria
Form 144 MACROGENICS INC. For: 27 September By Investing.com - Investing.com UK
MacroGenics stock falls 3.95 percent as pipeline expands - AD HOC NEWS
MacroGenics stock holds at USD 4.12 as cash strength stands out - AD HOC NEWS
Former MacroGenics (NASDAQ: MGNX) officer lines up another stock sale - stocktitan.net
MacroGenics stock edges lower as biotech analysts highlight risk and upside - AD HOC NEWS
MacroGenics2026 Funding Rounds & List of Investors - tracxn.com
MacroGenics (NASDAQ:MGNX): A Minervini Trend Template High-Growth Momentum Case Study - ChartMill
MGNX: Transformed structure, strong cash, and advancing antibody pipeline with key clinical milestones ahead - TradingView
MacroGenics at H.C. Wainwright conference: leaner model, rich pipeline - Investing.com
MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside - Stocktwits
MacroGenics CEO Eric Risser to present at H.C. Wainwright Global Investment Conference - Bitget
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX) - Seeking Alpha
MacroGenics (MGNX) Institutional Ownership 2026 - marketbeat.com
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Macrogenics Inc (MGNX) Senior VP, GC, and Secretary Jeffrey Pete - GuruFocus
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com Australia
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com Nigeria
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com Canada
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com South Africa
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com India
Macrogenics senior VP sells $129,085 in shares - Investing.com
MacroGenics (MGNX) counsel sells 31K shares, now holds none - Stock Titan
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
MacroGenics (NASDAQ: MGNX) officer prepares stock sales under Rule 144 - Stock Titan
MacroGenics (MGNX) Q1 2026 Results: The Bottom-Line Figure Beats Its Comparison in the Latest Session - vinanet.vn
MacroGenics (MGNX) exec adds 40K shares via option exercise - stocktitan.net
MacroGenics (NASDAQ: MGNX) insider lines up new stock sale after recent trade - stocktitan.net
MGNX Maintained by B. Riley Securities -- Price Target Raised to $11.00 - GuruFocus
B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating - marketscreener.com
MacroGenics (MGNX) Stock Faces A Revenue Reality Check After Deeper Losses - Sahm
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):